Emerging therapies for acute myeloid leukemia

Journal of Hematology and Oncology
10, 93
DOI: 10.1186/s13045-017-0463-6

Citation Report

#	Article	IF	Citations
1	Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Journal of Hematology and Oncology, 2017, 10, 128.	17.0	21
2	The Natural Antiangiogenic Compound AD0157 Induces Caspase-Dependent Apoptosis in Human Myeloid Leukemia Cells. Frontiers in Pharmacology, 2017, 8, 802.	3.5	5
3	Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia. Frontiers in Pharmacology, 2017, 8, 897.	3.5	13
4	New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology, 2017, 8, 1804.	4.8	54
5	Effect of sorafenib on the outcomes of patients with FLT3â€ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Cancer, 2018, 124, 1954-1963.	4.1	51
6	BCL11A and MDR1 expressions have prognostic impact in patients with acute myeloid leukemia treated with chemotherapy. Pharmacogenomics, 2018, 19, 343-348.	1.3	11
7	Venetoclax: A new wave in hematooncology. Experimental Hematology, 2018, 61, 10-25.	0.4	73
8	Control in dormancy or eradication of cancer stem cells: Mathematical modeling and stability issues. Journal of Theoretical Biology, 2018, 449, 103-123.	1.7	11
9	Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Instituteâ€designated cancer centers in California. Cancer, 2018, 124, 1938-1945.	4.1	40
10	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer Journal, 2018, 8, 4.	6.2	43
11	Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 769-773.	2.2	16
12	Protein kinase inhibitors for acute leukemia. Biomarker Research, 2018, 6, 8.	6.8	26
13	IMGN779, a Novel CD33-Targeting Antibodyâ€“Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. Molecular Cancer Therapeutics, 2018, 17, 1271-1279.	4.1	60
14	Mutation of the DNMT3A and IDH1/2 genes in Iranian acute myeloid leukemia patients with normal karyotype (CN-AML): association with other gene mutation and clinical and laboratory characteristics. Journal of Hematopathology, 2018, 11, 29-36.	0.4	2
15	Gliomas in Children. Seminars in Neurology, 2018, 38, 121-130.	1.4	15
16	Branched-chain amino acid metabolism in cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2018, 21, 64-70.	2.5	220
17	Occurrence of graftâ€versusâ€host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. Journal of Internal Medicine, 2018, 283, 178-189.	6.0	26
18	CD8 + T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clinical Immunology, 2018, 190, 64-73.	3.2	52

#	Article	IF	Citations
19	Molecular landscape and targeted therapy of acute myeloid leukemia. Biomarker Research, 2018, 6, 32.	6.8	24
20	Acute Myelogeneous Leukemia: Diagnosis and Treatment. , 2018, , 9-9.		0
21	FLT3 inhibitors in acute myeloid leukemia. Journal of Hematology and Oncology, 2018, 11, 133.	17.0	117
22	Development of a safety and efficacy nanoemulsion delivery system encapsulated gambogic acid for acute myeloid leukemia in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2018, 125, 172-180.	4.0	15
23	SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms. Biomarker Research, 2018, 6, 29.	6.8	13
24	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Letters, 2018, 438, 63-75.	7.2	116
25	Nanomedicines for the treatment of hematological malignancies. Journal of Controlled Release, 2018, 287, 194-215.	9.9	100
26	First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2018, 61, 8353-8373.	6.4	17
27	A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Advances, 2018, 2, 848-858.	5.2	125
28	Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report. Frontiers of Medicine, 2018, 12, 593-599.	3.4	6
29	Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e303-e314.	0.4	10
30	Cancer Metabolism: Current Understanding and Therapies. Chemical Reviews, 2018, 118, 6893-6923.	47.7	161
31	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15â€“60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. Annals of Hematology, 2018, 97, 1785-1795.	1.8	4
32	Antioxidant activity and leukemia initiation prevention inï¿½vitro and inï¿½vivo by Nâ€‘acetylâ€‘Lâ€‘cysteine. Oncology Letters, 2018, 16, 2046-2052.	1.8	16
33	A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/Î²-catenin pathways for treatment of AML with high PRL-3 phosphatase. Journal of Hematology and Oncology, 2018, 11, 36.	17.0	22
34	CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. Journal of Hematology and Oncology, 2018, 11, 7.	17.0	124
35	SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis. Biomarker Research, 2018, 6, 1.	6.8	31
36	A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. Molecular Therapy, 2018, 26, 2487-2495.	8.2	72

#	Article	IF	Citations
37	Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today, 2018, 23, 1936-1949.	6.4	40
38	Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients. Frontiers of Medicine, 2019, 13, 229-237.	3.4	18
39	Anticancer Alkaloids: Molecular Mechanisms and Clinical Manifestations. , 2019, , 1-35.		1
40	Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. Medicina (Lithuania), 2019, 55, 414.	2.0	18
41	HDAC2â€dependent miRNA signature in acute myeloid leukemia. FEBS Letters, 2019, 593, 2574-2584.	2.8	15
42	The Top 100 Highly Cited Original Articles on Immunotherapy for Childhood Leukemia. Frontiers in Pharmacology, 2019, 10, 1100.	3.5	10
43	Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomarker Research, 2019, 7, 22.	6.8	73
44	Establishment and characterization of a DOT1L inhibitorâ€sensitive human acute monocytic leukemia cell line YBTâ€5 with a novel KMT2Aâ€MLLT3 fusion. Hematological Oncology, 2019, 37, 617-625.	1.7	2
45	Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomarker Research, 2019, 7, 24.	6.8	39
46	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. Annals of Hematology, 2019, 98, 2467-2483.	1.8	9
47	Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. Journal of Hematology and Oncology, 2019, 12, 94.	17.0	70
48	Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research, 2019, 7, 19.	6.8	44
49	A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2019, 18, 567-578.	4.1	13
50	SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2307-2315.	2.2	7
51	MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388) . OncoTargets and Therapy, 2019, Volume 12, 2903-2910.	2.0	67
52	Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1674-1681.	2.0	24
53	Targeting CLL-1 for acute myeloid leukemia therapy. Journal of Hematology and Oncology, 2019, 12, 41.	17.0	56
54	Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia. Pediatric Blood and Cancer, 2019, 66, e27785.	1.5	4

#	Article	IF	Citations
55	Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. BMC Cancer, 2019, 19, 242.	2.6	6
56	Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells. Journal of Hematology and Oncology, 2019, 12, 30.	17.0	34
57	Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. Cancer Letters, 2019, 454, 171-178.	7.2	14
58	Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia. Hematology, Transfusion and Cell Therapy, 2019, 41, 169-177.	0.2	23
59	Cancer biomarkers for targeted therapy. Biomarker Research, 2019, 7, 25.	6.8	72
60	Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia. Medicine (United States), 2019, 98, e15948.	1.0	11
61	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. Journal of Internal Medicine, 2019, 285, 446-454.	6.0	4
62	Genetic characterization of ABT-199 sensitivity in human AML. Leukemia, 2020, 34, 63-74.	7.2	58
63	Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33. International Journal of Molecular Sciences, 2020, 21, 310.	4.1	18
64	Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells. Cancer Chemotherapy and Pharmacology, 2020, 85, 401-412.	2.3	10
65	Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library. European Journal of Medicinal Chemistry, 2020, 189, 112023.	5.5	13
66	Role of HDACs in normal and malignant hematopoiesis. Molecular Cancer, 2020, 19, 5.	19.2	124
67	The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options. Cancers, 2020, 12, 1898.	3.7	9
68	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and highâ€risk myelodysplastic syndrome. American Journal of Hematology, 2020, 95, 1457-1465.	4.1	2
69	Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabineâ€based chemotherapy. International Journal of Laboratory Hematology, 2020, 42, 849-857.	1.3	8
70	Development of a highly sensitive method for detection of FLT3D835Y. Biomarker Research, 2020, 8, 30.	6.8	3
71	Improving AML Classification Using Splicing Signatures. Clinical Cancer Research, 2020, 26, 3503-3504.	7.0	2
72	The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells. Frontiers in Oncology, 2020, 10, 799.	2.8	15

#	Article	IF	Citations
73	THBS1 Is a Novel Serum Prognostic Factors of Acute Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 1567.	2.8	18
74	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. Leukemia Research, 2020, 91, 106339.	0.8	20
75	A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia, 2021, 35, 1586-1596.	7.2	57
76	Targeting LSD1 for acute myeloid leukemia (AML) treatment. Pharmacological Research, 2021, 164, 105335.	7.1	44
77	Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Journal of Hematology and Oncology, 2021, 14, 4.	17.0	47
78	RSK Inhibition Induces Apoptosis by Downregulating Protein Synthesis in a Variety of Acute Myeloid Leukemia Cell Lines. Biological and Pharmaceutical Bulletin, 2021, 44, 1843-1850.	1.4	3
79	Circ_0058058 Knockdown Inhibits Acute Myeloid Leukemia Progression by Sponging miR-4319 to Regulate EIF5A2 Expression. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	1.0	6
80	Type of prior genotoxic insult determines the genomic characteristics of therapyâ€related myeloid neoplasms. American Journal of Hematology, 2021, 96, E223-E225.	4.1	2
81	A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis, 2021, 10, 39.	4.9	15
82	A novel polyethylene glycol (<scp>PEG</scp>)â€drug conjugate of Venetoclax, a Bclâ€2 inhibitor, for treatment of acute myeloid leukemia (<scp>AML</scp>). Cancer Reports, 2022, 5, e1485.	1.4	3
83	RSK Isoforms in Acute Myeloid Leukemia. Biomedicines, 2021, 9, 726.	3.2	6
84	MicroRNA-107 promotes apoptosis ofÂacute myelocytic leukemia cells by targeting RAD51. Archives of Medical Science, 2021, 17, 1044-1055.	0.9	5
85	The beginning of a new therapeutic era in acute myeloid leukemia. EJHaem, 2021, 2, 823-833.	1.0	3
86	Functional Roles of Bromodomain Proteins in Cancer. Cancers, 2021, 13, 3606.	3.7	28
87	DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clinical Epigenetics, 2021, 13, 166.	4.1	85
88	MicroRNAâ€‘93 knockdown inhibits acute myeloid leukemia cell growth via inactivating theÂPI3K/AKT pathway by upregulating DAB2. International Journal of Oncology, 2021, 59, .	3.3	8
89	Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. Critical Reviews in Oncology/Hematology, 2020, 152, 102993.	4.4	16
90	Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget, 2018, 9, 4301-4317.	1.8	22

#	Article	IF	Citations
91	Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy. Oncotarget, 2019, 10, 1250-1265.	1.8	18
92	RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget, 2020, 11, 2387-2403.	1.8	18
93	Venetoclax: evidence to date and clinical potential. Drugs in Context, 2019, 8, 1-13.	2.2	83
94	Acute Myeloid Leukemia: Is That All There Is?. Cureus, 2018, 10, e3198.	0.5	4
95	Sodium azulene sulfonate reverses multidrug resistance in K562/A02 cells. Cellular and Molecular Biology, 2019, 65, 105.	0.9	0
99	Targeting CD33 for acute myeloid leukemia therapy. BMC Cancer, 2022, 22, 24.	2.6	8
100	Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. American Journal of Blood Research, 2021, 11, 472-497.	0.6	2
101	SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance. International Journal of Molecular Sciences, 2022, 23, 2053.	4.1	19
102	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. Cancer Discovery, 2022, 12, 1560-1579.	9.4	13
108	Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma. Journal of Controlled Release, 2022, 348, 420-430.	9.9	4
109	The role of branched chain amino acids metabolic disorders in tumorigenesis and progression. Biomedicine and Pharmacotherapy, 2022, 153, 113390.	5.6	9
110	Circ_0035381 Regulates Acute Myeloid Leukemia Development by Modulating YWHAZ Expression via Adsorbing miR-582-3p. Biochemical Genetics, 2023, 61, 354-371.	1.7	3
111	Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge. Cancers, 2022, 14, 4111.	3.7	5
112	BET inhibitors: an updated patent review (2018â€“2021). Expert Opinion on Therapeutic Patents, 2022, 32, 953-968.	5.0	7
113	Heme oxygenase 1 overexpression induces immune evasion of acute myeloid leukemia against natural killer cells by inhibiting CD48. Journal of Translational Medicine, 2022, 20, .	4.4	7
115	Biomarkers as targets for CAR-T/NK cell therapy in AML. Biomarker Research, 2023, 11, .	6.8	6
116	Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies. Journal of Hematology and Oncology, 2023, 16, .	17.0	3
117	Optimization of Tyrosine Kinase Inhibitor-Loaded Gold Nanoparticles for Stimuli-Triggered Antileukemic Drug Release. Journal of Functional Biomaterials, 2023, 14, 399.	4.4	0

#	Article	IF	Citations
118	HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285. , 2023, 40, .		1
119	Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia. European Journal of Medicinal Chemistry, 2024, 264, 116015.	5.5	0